| (210) | Number of the EPO application | 19716296 |
| (220) | Filing date of the EPO application | 2019.03.01 |
| (80) | EPO patent specification publication (B) | EPB nr. 48/2024, 2024.11.27 |
| (110) | EPO patent number | 3758708 |
| (11) | Number of the document | MD 3758708 T2 |
| (21) | Number of the application | e 2021 0035 |
| (71) | Name(s) of applicant(s), code of the country | ASTRAZENECA AB, SE; |
| (72) | Name(s) of inventor(s), code of the country | WIKSTRÖM Håkan, SE;
LUDVIGSSON Jufang Wu, SE;
ANDERSSON Thomas, SE; |
| (73) | Name(s) of owner(s), code of the country | ASTRAZENECA AB, SE; |
| (54) | Title of the invention | Pharmaceutical compositions comprising (2s)-{(1s)-1-cyano-2-[4-(3-methyl-2-oxo-2,3-dihydro-1,3-benzoxazol-5-yl)phenyl]ethyl}-1,4-oxazepane-2-carboxamide |
| (13) | Kind-of-document code | T2 |
| (51) | International Patent Classification | A61K 31/553 (2006.01.01); A61P 11/06 (2006.01.01) |
| (19) | Country | SE |
| (41) | Date of publication of the application | 2021.01.31 |
| (49) | Date of publication of the translation of the validated European patent specification | 2025.04.30 |
| (30) | Priority | 201862636944 P, 2018.03.01, US |
| (74) | Patent attorney | (Procedură) CORCODEL Angela, Bd. Ştefan cel Mare nr. 134, Chişinău, Republica Moldova |
| (86) | International application | PCT/EP2019/055138, 2019.03.01 |
| (87) | International publication | WO 2019/166626, 2019.09.06 |